From-omics to personalized medicine in nephrology: Integration is the key

Nephrology Dialysis Transplantation

Volumn 28, Issue 1, 2013, Pages 24-28

  Pesce, Francesco ^a   Pathan, Saad ^b   Schena, Francesco Paolo ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Centro Addestramento Ricerca Scientifica in Oncologia (CARSO) Consortium   (Italy)

Author keywords

biomarkers; nephrology; omics; personalized medicine; systems biology

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEOME; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ELECTROSPRAY MASS SPECTROMETRY; FOCAL GLOMERULOSCLEROSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; GLOMERULUS FILTRATION RATE; HIGH THROUGHPUT SEQUENCING; HIV ASSOCIATED NEPHROPATHY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY POLYCYSTIC DISEASE; LIQUID CHROMATOGRAPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MASS FRAGMENTOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NEPHROLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PERSONALIZED MEDICINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEPHROLOGY; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 84872228488     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs483     Document Type: Review

References (54)

1. Kitano H. Systems biology: a brief overview. Science 2002; 295: 1662-1664
2. Bruggeman FJ, Westerhoff HV. The nature of systems biology. Trends Microbiol 2007; 15: 45-50
3. Ahn AC, Tewari M, Poon CS et al. The limits of reductionism in medicine: could systems biology offer an alternative? PLoS Med 2006; 3: e208-e209
4. Molina F, Dehmer M, Perco P et al. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant 2010; 25: 1015-1018
5. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327
6. Yu XQ, Li M, Zhang H et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 2012; 44: 178-182
7. Feehally J, Farrall M, Boland A et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010; 21: 1791-1797
8. Genovese G, Tonna SJ, Knob AU et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010; 78: 698-704
9. O'Seaghdha CM, Fox CS. Genome-wide association studies of chronic kidney disease: what have we learned? Nat Rev Nephrol 2012; 8: 89-99
10. Kottgen A, Pattaro C, Boger CA et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010; 42: 376-384
11. Hodgin JB, Cohen CD. Experimental approaches to the human renal transcriptome. Semin Nephrol 2010; 30: 455-467
12. Cox SN, Sallustio F, Serino G et al. Altered modulation of WNTbeta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int 2010; 78: 396-407
13. Cox SN, Sallustio F, Serino G et al. Activated innate immunity and involvement of the CX3CR1-FKN axis in promoting hematuria in IgA nephropathy patients. Kidney Int 2012, doi:10.1038/ki.2012.147
14. Martini S, Eichinger F, Nair V et al. Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord 2008; 9: 267-274
15. Hodgin JB, Borczuk AC, Nasr SH et al. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol 2010; 177: 1674-1686
16. Peterson KS, Huang JF, Zhu J et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004; 113: 1722-1733
17. Ju W, Eichinger F, Bitzer M et al. Renal gene and protein expression signatures for prediction of kidney disease progression. Am J Pathol 2009; 174: 2073-2085
18. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 2011; 12: 87-98
19. Wold B, Myers RM. Sequence census methods for functional genomics. Nat Methods 2008; 5: 19-21
20. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet 2009; 10: 669-680
21. Kato M, Park JT, Natarajan R. MicroRNAs and the glomerulus. Exp Cell Res 2012; 318: 993-1000
22. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518
23. Ho J, Ng KH, Rosen S et al. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 2008; 19: 2069-2075
24. Shi S, Yu L, Chiu C et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol 2008; 19: 2159-2169
25. Godwin JG, Ge X, Stephan K et al. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci USA 2010; 107: 14339-14344
26. Wang B, Herman-Edelstein M, Koh P et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010; 59: 1794-1802
27. Chung AC, Huang XR, Meng X et al. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 2010; 21: 1317-1325
28. Serino G, Sallustio F, Cox SN et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 2012; 23: 814-824
29. Wang G, Kwan BC, Lai FM et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers 2011; 30: 171-179
30. Wang G, Kwan BC, Lai FM et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers 2010; 28: 79-86
31. Te JL, Dozmorov IM, Guthridge JM et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 2010; 5: e10344
32. Wang G, Kwan BC, Lai FM et al. Intrarenal expression of micro-RNAs in patients with IgA nephropathy. Lab Invest 2010; 90: 98-103
33. Pandey P, Qin S, Ho J et al. Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease. BMC Syst Biol 2011; 5: 56
34. Papeta N, Chan KT, Prakash S et al. Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J Clin Invest 2009; 119: 1178-1188
35. Konvalinka A, Scholey JW, Diamandis EP. Searching for new biomarkers of renal diseases through proteomics. Clin Chem 2012; 58: 353-365
36. Papale M, Di Paolo S, Magistroni R et al. Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy. Diabetes Care 2010; 33: 2409-2415
37. Zhang X, Jin M, Wu H et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 2008; 74: 799-807
38. Rocchetti MT, Centra M, Papale M et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008; 8: 206-216
39. Metzger J, Chatzikyrkou C, Broecker V et al. Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl 2011; 5: 322-333
40. Mischak H, Ioannidis JP, Argiles A et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 2012; 42: 1027-1036
41. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2006; 2: 52
42. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol 2012; 8: 22-33
43. Shah AR, Singhal M, Klicker KR et al. Enabling high-throughput data management for systems biology: the Bioinformatics Resource Manager. Bioinformatics 2007; 23: 906-909
44. Shannon P, Markiel A, Ozier O et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504
45. Ghosh S, Matsuoka Y, Asai Y et al. Software for systems biology: from tools to integrated platforms. Nat Rev Genet 2011; 12: 821-832
46. Perco P, Mühlberger I, Mayer G et al. Linking transcriptomic and proteomic data on the level of protein interaction networks. Electrophoresis 2010; 31: 1780-1789
47. Matheis KA, Com E, Gautier JC et al. Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers. Toxicol Appl Pharmacol 2011; 252: 112-122
48. Lv H, Liu L, Zhang Y et al. Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Mol Biosyst 2010; 6: 2056-2067
49. Klein J, Jupp S, Moulos P et al. The KUPKB: a novel Web application to access multiomics data on kidney disease. FASEB J 2012; 26: 2145-2153
50. He JC, Chuang PY, Ma'ayan A et al. Systems biology of kidney diseases. Kidney Int 2012; 81: 22-39
51. Perco P, Oberbauer R. Integrative analysis of-omics data and histologic scoring in renal disease and transplantation: renal histogenomics. Semin Nephrol 2010; 30: 520-530
52. Trusheim MR, Berndt ER, Deuglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6: 287-293
53. Hood L, Heath JR, Phelps ME et al. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306: 640-643
54. Chen R, Mias GL, Li-Pook-Than J et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148: 1293-1307